Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921369 | 0.90 | RIPK1 (0.40) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL20580234 | 0.89 | RIPK1 (0.40) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL20580066 | 0.88 | RIPK1 (0.39) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL18921255 | 0.86 | RIPK1 (0.40) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL20580377 | 0.86 | RIPK1 (0.42) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL18921401 | 0.85 | RIPK1 (0.41) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL18921399 | 0.85 | RIPK1 (0.41) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL29966542 | 0.85 | RIPK1 (0.41) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL20580669 | 0.83 | RIPK1 (0.39) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 | |
| SCHEMBL18921452 | 0.83 | RIPK1 (0.43) | RIPK1CHRNB4CHRNA3CHRNA1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | APTUIT (VERONA) S.R.L. (IT) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885CHRNB4 3018/4885CHRNA3 2576/4885 |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885CHRNB4 3018/4885CHRNA3 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.